Are Psychedelics in Psychiatric Care Scientific Hype or the Future of Mental Health and Addiction Treatment?

Evidence To Date on Psychedelics in Psychiatric Care

Across the myriad of clinical trials and mechanistic studies, signals suggest rapid symptom reduction in treatment resistant depression (TRD) and post-traumatic stress disorder when psychedelic-assisted models are used, typically alongside structured psychotherapy. Recent work has explored psilocybin, MDMA and ketamine in depression^1-4, PTSD^5-7, and addictions^8-10 that have not responded to conventional approaches, including TRD¹. Trials report early improvements in symptom severity^3,9,11-13 and shifts in emotional openness or flexibility^14-17, particularly when dosing is embedded within a defined psychotherapeutic frame^18-19.

Mechanistically, the field is promising but still emerging^20-22, and implementation without rigorous training and protocolised care risks harm²². Interest has grown in neuroplasticity pathways potentially engaged by these compounds^23-26 and in effects relevant to fear extinction and learning reconsolidation^27-28. Methodological constraints persist, including small samples, blinding challenges, limited consideration of family psychiatric history, uncertainty around long-term outcomes, and uneven access^27,28-31. Ethical and safety considerations remain central – screening, preparation, and integration ought not be seen as optional add-ons, rather central to overall risk management^22,32-34.

MDMA-assisted therapy (MDMA-AT) in PTSD

Primary findings from randomised, double-blind, placebo-controlled, multi-site phase 3 trials (see³⁵) in severe PTSD showed significant attenuation on the CAPS-5 for MDMA-AT versus therapy with placebo, with improvements in transdiagnostic processes of self-experience often linked to poor outcomes with standard care³⁵. A second multicentre phase 3 trial³⁶, which studied MDMA-assisted therapy of patients with common comorbidities – including dissociation, depression, substance-use histories, childhood trauma – combined three preparatory with nine integrative sessions³⁵. It followed participants from baseline to two months and monitored adverse events and suicidality – reporting high efficacy and good tolerability in severe PTSD, including in those with comorbidity³⁵. There was evidence of maintained benefit from a similar study at 17–74 months post-treatment, in one cohort³⁶. However, it ought to be noted that adverse effects – such as bruxism, anxiety, jitteriness, headache and nausea – have been described and, critically, use of MDMA-AT outside a strongly controlled psychotherapeutic environment can carry considerable risk³⁷.

Ketamine in Treatment Resistant Depression

Approximately 10–20% of those living with depression meet criteria for treatment resistant depression³⁸, indicating a strong need to begin exploring alternative therapy modalities. Multiple studies indicate that the NMDA-antagonist, ketamine, can produce rapid antidepressant effects in treatment resistant depression, with clinically meaningful improvement observed within hours of administration³⁸. Studies had noted signals for reduction in suicidality in some cohorts, however limitations are notable³⁸. For example. long-term efficacy is under-characterised in most studies, and psychotomimetic properties complicate broader application³⁸. Ketamine for treatment resistant depression is generally considered safe when delivered within supervised protocols³⁹, but caution is advised in cases where those undertaking the treatment:

• Have existing psychotic disorders, as there is risk of exacerbation via dissociation³⁹
• Have histories of substance-use; given the euphoric feelings of the substance and
  therefore its potential for misuse³⁹, or
• Are adolescent, where long-term neurodevelopmental effects are uncertain³⁹.

The current landscape suggests that psychedelics in psychiatric care may catalyse rapid change for carefully selected patients when paired with structured psychotherapy and robust governance. The same literature underscores why screening, preparation, integration, and longitudinal follow-up are essential – and why caution remains warranted while larger, longer, and more pragmatic trials mature.

Clinical Relevance of Psychedelics In Psychiatric Care: Why Does This Matter Now?

Put simply: there is an unmet need. For example, treatment resistant depression carries a substantial personal and socioeconomic burden⁴⁰. And, for a proportion of patients, each successive conventional step can yield diminishing returns, even when delivered well and in line with guidance (as noted in⁴¹). This is the clinical backdrop against which interest in psychedelics in psychiatric care has been growing.

Early signals suggest these agents may create short-lived windows of increased cognitive–emotional flexibility in which stalled work can move again … a type of ‘psychological openess’. One report, for example, notes that “psychedelic substances induce transient emotional, perceptual, and cognitive alterations that may promote an optimal state of arousal likely required for effective trauma processing”⁴². In other words, they may help some patients access and tolerate highly effective psychotherapeutic modalities that are already rooted in an array of evidence, that may have been previously out of reach.

Crucially, any benefit appears closely tied to structure. Dosing should sit within a skilled, protocol-led psychotherapeutic frame; outside that container, risk rises through adverse effects, destabilisation, or misuse^37,39.

A Clinical Perspective on psychedelics in Psychiatric Care

There is promise here, bounded by clear parameters. Rapid symptom relief and short-lived state change have been observed across trials^3,9,11-13, with supportive signals in treatment resistant cohorts^38-39. Clinically, these transient shifts can open a window for stalled psychotherapeutic work – greater engagement, more tolerance for exposure, and movement where avoidance dominated. Crucially, the effective unit is medicine plus manualised, closely supervised therapy^18-19; outside that frame, the same state change risks destabilisation or harm²².

Design and bias issues may also temper studies – based on all literature discussed up to this point, common limitations and problems arise. For example, functional unblinding and expectancy effects may threaten internal validity. Participants (and sometimes therapists) may infer allocation, so monitoring for therapist-allegiance effects is essential. Secondly, small samples and selective eligibility reduce generalisability, and intensive protocols may not map neatly onto routine services. Lastly, adverse events – transient anxiety, dissociation, blood-pressure elevations, and rarer complications – must be consistently reported and recorded across every trial, completely transparently.

Finally, I believe screening remains central. A conservative approach excludes those with a personal or family history of psychosis or mania, where induced perceptual or dissociative states could aggravate vulnerability³⁹. Cardiovascular risk is also key – while trial populations typically screen for fitness, yet some still lack robust safety data in patients with established cardiovascular disease (ie see⁴³). Accordingly, preparation, monitored dosing, and formal integration are not optional; they are the scaffolding that keeps benefit and risk proportionate.

In short, psychedelics in psychiatric care merit cautious attention: pair the potential for rapid therapeutic traction with rigorous screening, manualised psychotherapy, and tight clinical governance – and be explicit about the limits of the current evidence.

The Real-World Implications of Psychedelics in Psychiatric Care

When patients raise interest in psychedelic options, the conversation should be steady and factual. Most indications remain experimental and regulatory positions vary, so it’s important to set expectations early around safety screens, structured preparation, supervised dosing days, and formal integration. Emphasise that any potential benefit depends on medicine delivered within a skilled psychotherapeutic frame with clear clinical governance, rather than on the compound alone.

If access ever does become available, the clearest fit is likely to be carefully selected cases of treatment-resistant depression after multiple adequate trials and psychotherapy, where esketamine has been considered or tried, or in post-traumatic stress presentations in which specialist trauma-focused therapy is established but progress is stalled by avoidance or arousal. Suitability also depends on practical readiness: the capacity to engage with intensive preparation, integration, monitoring, and reliable follow-up. It is important to reiterate here that Harbor London does not offer psychedelic-assisted therapy and neither endorses nor opposes it; our role is to provide balanced guidance to referrers and families.

For high-profile clients, risk management requires particular attention. Plan for privacy and documentation sensitivity, define media exposure safeguards, and agree crisis pathways in advance. If the UK enables access via licensed centres, steer toward clinics with robust governance: thorough medication reconciliation, cardiovascular and mental-state monitoring on dose days, trained and supervised therapists, transparent adverse-event reporting, and predefined criteria for escalation or discontinuation.

For referrers, the practical test is simple: decisions about psychedelics in psychiatric care should rest on eligibility, safety, and the patient’s capacity for tightly held psychotherapy and follow-through.

The Future of Psychedelics in Psychiatric Care

The signal around Psychedelics in psychiatric care is genuine in defined settings, yet methods, safety and implementation still need tightening.

Harbor’s position remains clear: we do not offer psychedelic-assisted therapy and have no plans to do so, but we will continue to follow the science. The generic elements that appear to matter – thorough preparation, skilled psychotherapy, careful dosing within a clinical frame and rigorous follow-up – are already embedded in our one-to-one, medically led approach to already-approved, evidence-backed treatment modalities.

If these treatments are licensed in the UK, priorities should be therapist training, robust governance, conservative screening and real-world outcomes tracking – especially for high-profile patients where privacy is paramount.

References

1. https://www.psych.theclinics.com/article/S0193-953X(23)00016-3/abstract
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC8209538/
3. https://journals.sagepub.com/doi/abs/10.1177/0269881120919957
4. https://journals.sagepub.com/doi/full/10.1177/2045125320950567
5. https://www.sciencedirect.com/science/article/abs/pii/S0022510X22001642
6. https://www.benthamdirect.com/content/journals/cn/10.2174/1570159X22666231027111147
7. https://academic.oup.com/ijnp/article/23/6/385/5805249
8. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1183740/full
9. https://link.springer.com/chapter/10.1007/7854_2022_327
10. https://www.sciencedirect.com/science/article/abs/pii/S2352154616302340
11. https://scholarlypublishingcollective.org/amhca/jmhc/article-abstract/42/4/323/389762/The-Role-of-Psychedelics-and-Counseling-in-Mental?redirectedFrom=PDF
12. https://link.springer.com/article/10.1007/s11033-020-06009-x
13. https://www.sciencedirect.com/science/article/abs/pii/S0165032722011818
14. https://journals.sagepub.com/doi/abs/10.1177/0269881119827891
15. https://akjournals.com/view/journals/2054/4/3/article-p163.xml
16. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2018.00897/full
17. https://www.sciencedirect.com/science/article/abs/pii/S2212144719301176
18. https://link.springer.com/article/10.1007/s12671-023-02206-4
19. https://psychiatryonline.org/doi/full/10.1176/appi.ajp.2019.19010035
20. https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1486-7386
21. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.727117/full
22. https://psychiatryonline.org/doi/full/10.1176/appi.ps.20220525
23. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.724606/full?trk=public_post_comment-text
24. https://www.nature.com/articles/s41386-022-01389-z
25. https://pubs.acs.org/doi/abs/10.1021/acs.biochem.1c00812
26. https://www.science.org/doi/full/10.1126/science.adf0435
27. https://www.nature.com/articles/s41386-022-01324-2
28. https://onlinelibrary.wiley.com/doi/abs/10.1002/jnr.25017
29. https://psycnet.apa.org/record/2020-39571-001
30. https://link.springer.com/article/10.1007/s40263-024-01101-3
31. https://www.tandfonline.com/doi/pdf/10.2147/RMHP.S300656
32. https://journals.sagepub.com/doi/abs/10.1177/0004867421998785
33. https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/article/ethical-issues-regarding-nonsubjective-psychedelics-as-standard-of-care/E32BC689D0FCB82FAB4484CA87CEB922
34. https://www.sciencedirect.com/science/article/pii/S0028390822002246
35. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0295926&
36. https://journals.sagepub.com/doi/full/10.1177/0269881112456611
37. https://www.nature.com/articles/s41591-021-01336-3
38. https://pmc.ncbi.nlm.nih.gov/articles/PMC4243034/
39. https://www.health.harvard.edu/blog/ketamine-for-treatment-resistant-depression-when-and-where-is-it-safe-202208092797
40. https://pmc.ncbi.nlm.nih.gov/articles/PMC11008705/
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC6982454/
42. https://pmc.ncbi.nlm.nih.gov/articles/PMC10845102/pdf/CN-22-636.pdf
43. https://link.springer.com/article/10.1007/s43440-023-00539-4